Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Neurologists who Treat Epilepsy (US)

Analysis of: Allon's Phase II clinical trial shows statistically significant efficacy on human cognition and memory (www.pipelinereview.com)
WE need more options to fight against AD
February 27, 2008
It is dangerous move
Analysis of: Google to store patients' health records (news.yahoo.com)
It is not safe place to store personal health information in public search engine.
Analysis of: FORSTEO(R) Receives Positive Opinion from the European Committee for Medicinal Products for Human Use for the Treatment of Glucocorticoid-Induced Osteoporosis (www.pipelinereview.com)
Glucocorticoid-induced osteoporosis has been major problems for the people who use long-term steroid.
Analysis of: Crackdown on Big Pharma (money.cnn.com)
Big pharms have a lot of money to make things to the way they want. Fortunately, someone is trying to make it change
February 21, 2008
More than just AVASTIN
Analysis of: Genentech has billions at stake in FDA battle (sanfrancisco.bizjournals.com)
Genentech will have more battles to fight in the future aside from Avastin.  This medication appears extremely promising for the treatment of breast cancer, however, physicians are still mixed in their opinions about its place in the treatment of breast cancer.
February 15, 2008
Gamunex in CIDP
Analysis of: Positive Results from Phase III Trial of Gamunex in Patients with CIDP (pharmalive.com)
IVIg (intraveonus immunoglobulin) reduces disability and reduces risk of relapse in patients with CIDP (chronic inflammatory demyelinating polyradiculoneuropathy).
Daniel Wynn, MD, Director, Clinical Research
Daniel Wynn, MD, Director, Clinical Research
Consultants In Neurology Ltd.
Analysis of: Positive Results from Phase III Trial of Gamunex in Patients with CIDP (pharmalive.com)
Talecris' form of IVIG, Gamunex was studied in the largest trial of IVIG in chronic inflammatory polyradiculoneuropathy (CIDP), with more than twice as many patients moving into remission.  CIDP is a common acquired autoimmune peripheral neuropathy, which if not treated, may lead to a peripheral...
February 14, 2008
Effective treatment of MS
Analysis of: The call for a cure (www.indystar.com)
It has always been the dream for neurologists  and MS patients that one day, a magic drug will stop the progression even cure of the disease
Analysis of: Alphatec Holdings, Inc. Acquires An Exclusive Worldwide License for Innovative Dynamic Anterior Cervical Plate Technology (www.healthpointcapital.com)
Alphatec product line will expand and increase their market share The cervical plate from Progressive is much more promising than the Trestle plate developed by Alphatec, and should increase sales and improve the cervical implant portfolio
Analysis of: Efficacy of Botulinum Toxin Does Not Sag Over Time (www.medscape.com)
The long term efficacy of botulinum toxin Type A for the treatment of glabellar frown lines was recently discussed  in San Antonio, Texas at the 66th annual meeting of the American Association of Dermatology. Kawashima and other fellow Japanese investigators presented long-term (64 weeks)...

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Next41 to 50 of 156

Analytics


Generated at 2009-01-07T13:00:17.563